Literature DB >> 26795390

[Long-term outcomes of two different treatment concepts with HDR brachytherapy boost for intermediate-risk prostate cancer].

Nina Seibold1, György Kovács2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26795390     DOI： 10.1007/s00066-015-0937-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy.

Authors:  Yoshiya Yamada; Leland Rogers; D Jeffrey Demanes; Gerard Morton; Bradley R Prestidge; Jean Pouliot; Gil'ad N Cohen; Marco Zaider; Mihai Ghilezan; I-Chow Hsu
Journal:  Brachytherapy       Date:  2012 Jan-Feb       Impact factor: 2.362

2.  Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT.

Authors:  Israel Deutsch; Michael J Zelefsky; Zhigang Zhang; Qianxing Mo; Marco Zaider; Gil'ad Cohen; Oren Cahlon; Yoshiya Yamada
Journal:  Brachytherapy       Date:  2010-08-04       Impact factor: 2.362

3.  Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

Authors:  Peter J Hoskin; Ana M Rojas; Peter J Bownes; Gerry J Lowe; Peter J Ostler; Linda Bryant
Journal:  Radiother Oncol       Date:  2012-02-16       Impact factor: 6.280

4.  Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?

Authors:  Gerard Morton; Andrew Loblaw; Patrick Cheung; Ewa Szumacher; Manraj Chahal; Cyril Danjoux; Hans T Chung; Andrea Deabreu; Alexandre Mamedov; Liying Zhang; Raxa Sankreacha; Eric Vigneault; Colvin Springer
Journal:  Radiother Oncol       Date:  2011-09-14       Impact factor: 6.280

5.  Fractionation and protraction for radiotherapy of prostate carcinoma.

Authors:  D J Brenner; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

Review 6.  Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations.

Authors:  Nicholas J Sanfilippo; Benjamin T Cooper
Journal:  Am J Clin Exp Urol       Date:  2014-12-25

7.  Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.

Authors:  Gerard C Morton; D Andrew Loblaw; Raxa Sankreacha; Andrea Deabreu; Liying Zhang; Alexandre Mamedov; Patrick Cheung; Brian Keller; Cyril Danjoux; Ewa Szumacher; Gillian Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

Review 8.  GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update.

Authors:  Peter J Hoskin; Alessandro Colombo; Ann Henry; Peter Niehoff; Taran Paulsen Hellebust; Frank-Andre Siebert; Gyorgy Kovacs
Journal:  Radiother Oncol       Date:  2013-06-14       Impact factor: 6.280

9.  Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.

Authors:  Bradley R Pieters; Jeroen B van de Kamer; Yvonne R J van Herten; Niek van Wieringen; Greet M D'Olieslager; Uulke A van der Heide; Caro C E Koning
Journal:  Radiother Oncol       Date:  2008-04-02       Impact factor: 6.280

10.  Providing a fast conversion of total dose to biological effective dose (BED) for hybrid seed brachytherapy.

Authors:  Jakub Pritz; Kenneth M Forster; Amarjit S Saini; Matthew C Biagioli; Geoffrey G Zhang
Journal:  J Appl Clin Med Phys       Date:  2012-09-06       Impact factor: 2.102
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.